{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:45:08Z","timestamp":1784202308659,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T00:00:00Z","timestamp":1505952000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T00:00:00Z","timestamp":1505952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","award":["Investigator-Initiated Research grant"],"award-info":[{"award-number":["Investigator-Initiated Research grant"]}],"id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AR042743"],"award-info":[{"award-number":["R01-AR042743"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AR050511"],"award-info":[{"award-number":["R01-AR050511"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1417-7","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T12:02:53Z","timestamp":1505995373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study"],"prefix":"10.1186","volume":"19","author":[{"given":"Deepak R.","family":"Jadon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Nightingale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Dunphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Elder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan P.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Korendowych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,21]]},"reference":[{"issue":"1","key":"1417_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3899\/jrheum.140223","volume":"42","author":"DR Jadon","year":"2014","unstructured":"Jadon DR, Nightingale AL, McHugh NJ, Lindsay MA, Korendowych E, Sengupta R. Serum soluble bone turnover biomarkers in psoriatic arthritis and psoriatic spondyloarthropathy. J Rheumatol. 2014;42(1):21\u201330.","journal-title":"J Rheumatol"},{"issue":"4","key":"1417_CR2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/annrheumdis-2016-209853","volume":"76","author":"DR Jadon","year":"2016","unstructured":"Jadon DR, Sengupta R, Nightingale A, Lindsay M, Korendowych E, Robinson G, et al. Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis. 2016;76(4):701\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1417_CR3","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1417_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3899\/jrheum.110845","volume":"39","author":"W Tillett","year":"2012","unstructured":"Tillett W, Jadon D, Costa L, Wallis D, Cavill C, McHugh J, et al. The Classification for Psoriatic Arthritis (CASPAR) criteria - a retrospective feasibility, sensitivity, and specificity study. J Rheumatol. 2012;39(1):154\u20136.","journal-title":"J Rheumatol"},{"issue":"4","key":"1417_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361\u20138.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1417_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/rheumatology\/kes254","volume":"52","author":"D Jadon","year":"2013","unstructured":"Jadon D, Tillett W, Wallis D, Cavill C, Bowes J, Waldron N, et al. Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritis. Rheumatology (Oxford). 2013;52(2):261\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"1417_CR7","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.3899\/jrheum.090412","volume":"36","author":"V Chandran","year":"2009","unstructured":"Chandran V, Barrett J, Schentag CT, Farewell VT, Gladman DD. Axial psoriatic arthritis: update on a longterm prospective study. J Rheumatol. 2009;36(12):2744\u201350.","journal-title":"J Rheumatol"},{"issue":"5","key":"1417_CR8","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3899\/jrheum.080491","volume":"36","author":"E Lubrano","year":"2009","unstructured":"Lubrano E, Marchesoni A, Olivieri I, D\u2019Angelo S, Spadaro A, Parsons WJ, et al. Psoriatic arthritis spondylitis radiology index: a modified index for radiologic assessment of axial involvement in psoriatic arthritis. J Rheumatol. 2009;36(5):1006\u201311.","journal-title":"J Rheumatol"},{"issue":"1","key":"1417_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/ard.2004.020503","volume":"64","author":"MCW Creemers","year":"2005","unstructured":"Creemers MCW. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64(1):127\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1417_CR10","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S8756-3282(02)00728-7","volume":"30","author":"JA Clowes","year":"2002","unstructured":"Clowes JA. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone. 2002;30(6):886\u201390.","journal-title":"Bone"},{"issue":"5","key":"1417_CR11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/art.20696","volume":"51","author":"C Yang","year":"2004","unstructured":"Yang C, Gu J, Rihl M, Baeten D, Huang F, Zhao M, et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum. 2004;51(5):691\u20139.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1417_CR12","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1002\/art.20477","volume":"50","author":"B Vandooren","year":"2004","unstructured":"Vandooren B, Kruithof E, Yu DTY, Rihl M, Gu J, De Rycke L, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor-alpha blockade in spondylarthropathy. Arthritis Rheum. 2004;50(9):2942\u201353.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1417_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/ard.2010.138883","volume":"70","author":"SJ Pedersen","year":"2011","unstructured":"Pedersen SJ, Sorensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFalpha inhibitors. Ann Rheum Dis. 2011;70(8):1375\u201381.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1417_CR14","first-page":"2030","volume":"35","author":"WP Maksymowych","year":"2008","unstructured":"Maksymowych WP, Rahman P, Shojania K, Olszynski WP, Thomson GT, Ballal S, et al. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol. 2008;35(10):2030\u20137.","journal-title":"J Rheumatol"},{"issue":"1","key":"1417_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/art.27231","volume":"62","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis S-NC, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum. 2010;62(1):150\u20138.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1417_CR16","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3899\/jrheum.131199","volume":"41","author":"E Klingberg","year":"2014","unstructured":"Klingberg E, Nurkkala M, Carlsten H, Forsblad-d\u2019Elia H. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J Rheumatol. 2014;41(7):1349\u201356.","journal-title":"J Rheumatol"},{"issue":"5","key":"1417_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3899\/jrheum.100089","volume":"38","author":"SY Wang","year":"2011","unstructured":"Wang SY, Liu YY, Ye H, Guo JP, Li R, Liu X, et al. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol. 2011;38(5):821\u20137.","journal-title":"J Rheumatol"},{"issue":"9","key":"1417_CR18","first-page":"1527","volume":"60","author":"Z Yucong","year":"2014","unstructured":"Yucong Z, Lu L, Shengfa L, Yongliang Y, Ruguo S, Yikai L. Serum functional dickkopf-1 levels are inversely correlated with radiographic severity of ankylosing spondylitis. Clin Lab. 2014;60(9):1527\u201331.","journal-title":"Clin Lab"},{"issue":"7194","key":"1417_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nature06894","volume":"453","author":"L Yang","year":"2008","unstructured":"Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M, et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature. 2008;453(7194):524\u20138.","journal-title":"Nature"},{"issue":"6","key":"1417_CR20","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/j.1365-2133.2007.08195.x","volume":"157","author":"PJ Hampton","year":"2007","unstructured":"Hampton PJ, Ross OK, Reynolds NJ. Increased nuclear beta-catenin in suprabasal involved psoriatic epidermis. Br J Dermatol. 2007;157(6):1168\u201377.","journal-title":"Br J Dermatol"},{"issue":"Pt 2","key":"1417_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1242\/jcs.03329","volume":"120","author":"MT Teh","year":"2007","unstructured":"Teh MT, Blaydon D, Ghali LR, Briggs V, Edmunds S, Pantazi E, et al. Role for WNT16B in human epidermal keratinocyte proliferation and differentiation. J Cell Sci. 2007;120(Pt 2):330\u20139.","journal-title":"J Cell Sci"},{"issue":"5","key":"1417_CR22","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/sj.jid.5700629","volume":"127","author":"Y Yamaguchi","year":"2007","unstructured":"Yamaguchi Y, Passeron T, Watabe H, Yasumoto K, Rouzaud F, Hoashi T, et al. The effects of dickkopf 1 on gene expression and Wnt signaling by melanocytes: mechanisms underlying its suppression of melanocyte function and proliferation. J Invest Dermatol. 2007;127(5):1217\u201325.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1417_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/sj.jid.5700488","volume":"127","author":"J Reischl","year":"2007","unstructured":"Reischl J, Schwenke S, Beekman JM, Mrowietz U, Sturzebecher S, Heubach JF. Increased expression of Wnt5a in psoriatic plaques. J Invest Dermatol. 2007;127(1):163\u20139.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"1417_CR24","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1038\/jid.2010.67","volume":"130","author":"JE Gudjonsson","year":"2010","unstructured":"Gudjonsson JE, Johnston A, Stoll SW, Riblett MB, Xing X, Kochkodan JJ, et al. Evidence for altered Wnt signaling in psoriatic skin. J Invest Dermatol. 2010;130(7):1849\u201359.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1417_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2340\/00015555-1970","volume":"95","author":"O Seifert","year":"2015","unstructured":"Seifert O, Soderman J, Skarstedt M, Dienus O, Matussek A. Increased expression of the Wnt signalling inhibitor Dkk-1 in non-lesional skin and peripheral blood mononuclear cells of patients with plaque psoriasis. Acta Derm Venereol. 2015;95(4):407\u201310.","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"1417_CR26","first-page":"2236","volume":"31","author":"H Franck","year":"2004","unstructured":"Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol. 2004;31(11):2236\u201341.","journal-title":"J Rheumatol"},{"issue":"2","key":"1417_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/ard.53.2.117","volume":"53","author":"S Donnelly","year":"1994","unstructured":"Donnelly S, Doyle DV, Denton A, Rolfe I, McCloskey EV, Spector TD. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis. 1994;53(2):117\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1417_CR28","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3899\/jrheum.120316","volume":"39","author":"E Klingberg","year":"2012","unstructured":"Klingberg E, Geijer M, Gothlin J, Mellstrom D, Lorentzon M, Hilme E, et al. Vertebral fractures in ankylosing spondylitis are associated with lower bone mineral density in both central and peripheral skeleton. J Rheumatol. 2012;39(10):1987\u201395.","journal-title":"J Rheumatol"},{"issue":"12","key":"1417_CR29","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.3899\/jrheum.100483","volume":"37","author":"SM Reddy","year":"2010","unstructured":"Reddy SM, Anandarajah AP, Fisher MC, Mease PJ, Greenberg JD, Kremer JM, et al. Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry. J Rheumatol. 2010;37(12):2566\u201372.","journal-title":"J Rheumatol"},{"issue":"10","key":"1417_CR30","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/rheumatology\/kel072","volume":"45","author":"HR Kim","year":"2006","unstructured":"Kim HR, Lee SH, Kim HY. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford). 2006;45(10):1197\u2013200.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"1417_CR31","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s10067-010-1543-y","volume":"29","author":"CH Chen","year":"2010","unstructured":"Chen CH, Chen HA, Liao HT, Liu CH, Tsai CY, Chou CT. Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin Rheumatol. 2010;29(10):1155\u201361.","journal-title":"Clin Rheumatol"},{"key":"1417_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/1471-2474-13-191","volume":"13","author":"A Taylan","year":"2012","unstructured":"Taylan A, Sari I, Akinci B, Bilge S, Kozaci D, Akar S, et al. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord. 2012;13:191.","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"1417_CR33","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/art.21896","volume":"54","author":"PP Geusens","year":"2006","unstructured":"Geusens PP, Landewe RB, Garnero P, Chen D, Dunstan CR, Lems WF, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum. 2006;54(6):1772\u20137.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1417_CR34","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3899\/jrheum.121162","volume":"40","author":"V Chandran","year":"2013","unstructured":"Chandran V, Shen H, Pollock RA, Pellett FJ, Carty A, Cook RJ, et al. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis. J Rheumatol. 2013;40(6):866\u201371.","journal-title":"J Rheumatol"},{"issue":"1","key":"1417_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/annrheumdis-2012-201697","volume":"72","author":"CL Wagner","year":"2013","unstructured":"Wagner CL, Visvanathan S, Elashoff M, McInnes IB, Mease PJ, Krueger GG, et al. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis. 2013;72(1):83\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1417_CR36","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.intimp.2014.05.031","volume":"21","author":"KR de Andrade","year":"2014","unstructured":"de Andrade KR, de Castro GR, Vicente G, da Rosa JS, Nader M, Pereira IA, et al. Evaluation of circulating levels of inflammatory and bone formation markers in axial spondyloarthritis. Int Immunopharmacol. 2014;21(2):481\u20136.","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"1417_CR37","first-page":"1753","volume":"34","author":"JH Woo","year":"2007","unstructured":"Woo JH, Lee HJ, Sung IH, Kim TH. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol. 2007;34(8):1753\u20139.","journal-title":"J Rheumatol"},{"issue":"11","key":"1417_CR38","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s10067-010-1528-x","volume":"29","author":"SJ Pedersen","year":"2010","unstructured":"Pedersen SJ, Hetland ML, Sorensen IJ, Ostergaard M, Nielsen HJ, Johansen JS. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3\u00a0years of treatment with TNF alpha inhibitors. Clin Rheumatol. 2010;29(11):1301\u20139.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"1417_CR39","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s00296-011-1981-0","volume":"32","author":"SR Kwon","year":"2012","unstructured":"Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY, et al. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int. 2012;32(8):2523\u20137.","journal-title":"Rheumatol Int"},{"issue":"5","key":"1417_CR40","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1186\/ar2537","volume":"10","author":"H Appel","year":"2008","unstructured":"Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res Ther. 2008;10(5):R125.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"1417_CR41","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.3899\/jrheum.101128","volume":"38","author":"S Arends","year":"2011","unstructured":"Arends S, van der Veer E, Groen H, Houtman PM, Jansen TL, Leijsma MK, et al. Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis. J Rheumatol. 2011;38(8):1644\u201350.","journal-title":"J Rheumatol"},{"issue":"4","key":"1417_CR42","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/rheumatology\/kei208","volume":"45","author":"CH Chen","year":"2006","unstructured":"Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford). 2006;45(4):414\u201320.","journal-title":"Rheumatology (Oxford)"},{"key":"1417_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1471-2474-15-93","volume":"15","author":"S Sun","year":"2014","unstructured":"Sun S, Bay-Jensen AC, Karsdal MA, Siebuhr AS, Zheng Q, Maksymowych WP, et al. The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases. BMC Musculoskelet Disord. 2014;15:93.","journal-title":"BMC Musculoskelet Disord"},{"issue":"Pt 19","key":"1417_CR44","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1242\/jcs.00063","volume":"115","author":"AH Baker","year":"2002","unstructured":"Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002;115(Pt 19):3719\u201327.","journal-title":"J Cell Sci"},{"issue":"20","key":"1417_CR45","doi-asserted-by":"crossref","first-page":"11539","DOI":"10.1016\/S0021-9258(18)80094-1","volume":"264","author":"L Sottrup-Jensen","year":"1989","unstructured":"Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem. 1989;264(20):11539\u201342.","journal-title":"J Biol Chem"},{"issue":"4","key":"1417_CR46","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1136\/annrheumdis-2011-200216","volume":"71","author":"GR Heiland","year":"2012","unstructured":"Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(4):572\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1417_CR47","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/ard.61.2.161","volume":"61","author":"C Ribbens","year":"2001","unstructured":"Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis. 2001;61(2):161\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1417_CR48","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1530\/eje.0.1400332","volume":"140","author":"A Schlemmer","year":"1999","unstructured":"Schlemmer A, Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. European journal of endocrinology\/European Federation of Endocrine Societies. 1999;140(4):332\u20137.","journal-title":"European journal of endocrinology\/European Federation of Endocrine Societies"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1417-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-017-1417-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1417-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T04:20:26Z","timestamp":1659500426000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1417-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,21]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1417"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1417-7","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,21]]},"assertion":[{"value":"5 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed with ethical approval from the Frenchay Regional Ethics Committee (12\/SW\/0110) and Institutional Review Boards of the Royal National Hospital for Rheumatic Diseases (RBB376) and University of Michigan, with written consent from participants, and in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"210"}}